Regorafenib: A review of its use in previously treated patients with progressive metastatic colorectal cancer

Drugs and Aging

Volumn 31, Issue 1, 2014, Pages 67-78

  Carter, Natalie J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; ANTIINFECTIVE AGENT; B RAF KINASE; CARBAMAZEPINE; CLARITHROMYCIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIRTECAN; FLUOROURACIL; IRINOTECAN; ITRACONAZOLE; KETOCONAZOLE; MIDAZOLAM; OMEPRAZOLE; OXALIPLATIN; PHENOBARBITAL; PHENYTOIN; PLACEBO; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN RET; RAF PROTEIN; REGORAFENIB; RIFAMPICIN; ROSIGLITAZONE; STEM CELL FACTOR RECEPTOR; TELITHROMYCIN; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3; WARFARIN;

ABNORMAL LABORATORY RESULT; ADVERSE DRUG REACTION; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; GRAPEFRUIT JUICE; HUMAN; HYPERICUM PERFORATUM; JAPANESE; LIVER METASTASIS; MAXIMUM PLASMA CONCENTRATION; METASTATIC COLORECTAL CANCER; MILD RENAL IMPAIRMENT; MODERATE RENAL IMPAIRMENT; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NONHUMAN; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEVERE RENAL IMPAIRMENT; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR ASSOCIATED LEUKOCYTE;

COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; NEOPLASM METASTASIS; PHENYLUREA COMPOUNDS; PYRIDINES; TREATMENT OUTCOME;

EID: 84892914903     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0140-6     Document Type: Article

References (42)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69-90.
2. Troiani T, Martinelli E, Orditura M, et al. Beyond bevacizumab: new anti-VEGF strategies in colorectal cancer. Expert Opin Investig Drugs. 2012;21(7):949-59.
3. Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer. 2012; 11(1):1-13.
4. American Cancer Society. Cancer facts and figures. http://www.cancer.org/ acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf (2013). Accessed 16 May 2013.
5. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: colon cancer, version 3.2013. http://www.nccn.org/professionals/ physician-gls/pdf/colon.pdf(2013). Accessed 17 May 2013.
6. McCormack PL, Keam SJ. Bevacizumab: A review of its use in metastatic colorectal cancer. Drugs. 2008;68(4):487-506.
7. Blick SKA, Scott LJ. Cetuximab: A review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer. Drugs. 2007;67(17):2585-607.
8. Keating GM. Panitumumab: A review of its use in metastatic colorectal cancer. Drugs. 2010;70(8):1059-78.
9. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: rectal cancer, version 4.2013. http://www.nccn.org/professionals/ physician-gls/pdf/rectal.pdf(2013). Accessed 17 May 2013.
10. Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res. 2010;16:3811-8.
11. Gossage L, Eisen T. Targeting multiple kinase pathways: A change in paradigm. Clin Cancer Res. 2010;16:1973-8.
12. Faivre S, Djelloul S, Raymond E. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol. 2006;33:407-20.
13. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59:111-37.
14. Bayer Pharma AG. Stivarga (regorafenib) tablets: EU summary of product characteristics. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Product-Information/human/002573/WC500149164.pdf (2013). Accessed 2 Oct 2013.
15. Bayer HealthCare Pharmaceuticals Inc. Stivarga (regorafenib) tablets: US prescribing information. http://www.accessdata.fda.gov/drugsatfda-docs/label/ 2013/203085s001lbl.pdf (2013). Accessed 24 Jul 2013.
16. Bayer Inc. Stivarga (regorafenib tablets): Canadian product monograph. Toronto: Bayer Inc.; 2013.
17. Bayer. Stivarga (regorafenib tablets): Japanese prescribing information. Osaka: Bayer; 2013.
18. Schmoll H, Van Cutsem E, Stein A, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol. 2012;23(10):2479-516.
19. Center for Drug Evaluation and Research. Regorafenib (Stivarga): CDER medical review. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2012/ 203085Orig1s000MedR.pdf (2012). Accessed 16 Apr 2013.
20. Aprile G, Macerelli M, Giuliani F. Regorafenib for gastrointestinal malignancies: from preclinical data to clinical results of a novel multi-target inhibitor. BioDrugs. 2013;27(3):213-24.
21. Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromaland oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245-55.
22. Schmieder R, Ellinghaus P, Scholz A, et al. Regorafenib (BAY 73-4506): anti-metastatic activity in a mouse model of colorectal cancer [abstract no. 2337]. American Association for Cancer Research Annual Meeting; 31 Mar-4 Apr 2012; Chicago (IL).
23. Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(9):2658-67.
24. Strumberg D, Scheulen ME, Schultheis B, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: A phase I study. Br J Cancer. 2012;106(11):1722-7.
25. Abou-Elkacem L, Arns S, Brix G, et al. Regorafenib inhibits growth, angiogenesis and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther. 2013. doi:10. 1158/1535-7163.MCT-12-1162.
26. Loges S, Schmidt T, Carmeliet P. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. Gene Can. 2010;1(1):12-25.
27. Lenz H-J, Van Cutsem E, Sobrero AF, et al. Analysis of plasma protein biomarkers from the CORRECT phase III study of regorafenib for metastatic colorectal cancer [abstract no. 3514]. J Clin Oncol. 2013;31(15 Suppl).
28. de Jesus-Gonzalez N, Robinson E, Penchev R, et al. Regorafenib induces rapid and reversible changes in plasma nitric oxide and endothelin-1. Am J Hypertens. 2012;25(10):1118-23.
29. Bayer. Open label regorafenib study to evaluate cardiovascular safety parameters, tolerability, and anti-tumor activity [Clinical- Trials.gov identifier NCT01339104] US National Institutes of Health, ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01339104?term=regorafenib? cardiovascular&rank=1 (2013). Accessed 24 Jul 2013.
30. Sunakawa Y, Furuse J, Okusaka T, et al. Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Invest New Drugs. 2013. doi:10.1007/s10637- 013-9953-8.
31. Schultheis B, Folprecht G, Kuhlmann J, et al. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol. 2013;24(6):1560-7.
32. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebocontrolled, phase 3 trial. Lancet. 2013;381(9863):303-12.
33. Van Cutsem EJD, Grothey A, Sobrero A, et al. Phase 3 CORRECT trial of regorafenib in metastatic colorectal cancer (mCRC): overall survival update [abstract no. LBA18]. Ann Oncol. 2012;23(Suppl 9):ixe10.
34. Jeffers M, Van Cutsem E, Sobrero AF, et al. Mutational analysis of biomarker samples from the CORRECT study: correlating mutation status with clinical response to regorafenib [abstract no. 381]. J Clin Oncol. 2013;31(4 Suppl).
35. Grothey A, Sobrero AF, Siena S, et al. Time profile of adverse events (AEs) from regorafenib (REG) treatment for metastatic colorectal cancer (mCRC) in the phase III CORRECT study [abstract no. 3637]. J Clin Oncol. 2013;31(15 Suppl).
36. Bayer. Bayer's Stivarga(R) approved for the treatment of patients with gastrointestinal stromal tumors in Japan. http://www.press.bayer.com/baynews/ baynews.nsf/id/Bayers-Stivarga-Approved-Treatment-Patients-Gastrointestinal- Stromal-Tumors-Japan?OpenDocument&sessionID=1377122611(2013). Accessed 21 Aug 2013.
37. Bayer. First line treatment of metastatic colorectal cancer with mFOLFOX6 in combination with regorafenib [ClinicalTrials.gov identifier NCT01289821] US National Institutes of Health, ClinicalTrials.gov. http://clinicaltrials.gov/ ct2/show/NCT01289821?term=regorafenib?colorectal?cancer&rank=7 (2012). Accessed 20 May 2013.
38. UNC Lineberger Comprehensive Cancer Center. Regorafenib ? FOLFIRI versus placebo ? FOLFIRI as 2nd line Tx in metastatic colorectal cancer [ClinicalTrials.gov identifier NCT01298570] US National Institutes of Health, ClinicalTrials. gov. http://clinicaltrials.gov/ct2/show/NCT01298570?term= regorafenib?colorectal?cancer&rank=3(2013) Accessed 20 May 2013.
39. Lacouture ME, Wu S, Robert C, et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13:1001-11.
40. Anderson R, Jatoi A, Robert C, et al. Search for evidence-based approaches for the prevention and palliation of hand-foot skin reaction (HFSR) caused by multikinase inhibitors (MKIs). Oncologist. 2009;14:291-302.
41. Wood LS, Lemont H, Jatoi A, et al. Practical considerations in the management of hand-foot skin reaction caused by multikinase inhibitors. Comm Oncol. 2010;7(1):23-9.
42. Bayer. Regorafenib in subjects with metastatic colorectal cancer (CRC) who have progressed after standard therapy (CONSIGN) [ClinicalTrials.gov identifier NCT01538680] US National Institutes of Health, ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT01538680?term=regorafenib?colorectal? cancer&rank=6(2013) Accessed 20 May 2013.